newsfilter
← Latest News
GlobeNewswire·

Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

  • Tenaya Therapeutics announced that its executive team will present at the Jefferies Global Healthcare Conference in New York from June 2-4, 2026.
  • CEO Faraz Ali is scheduled to deliver a company presentation on Thursday, June 4, 2026, at 3:10 p.m. ET.
  • The presentation will be live-streamed via the Investors section of Tenaya's website, with an archived replay available for approximately 30 days.
  • Tenaya's clinical pipeline includes TN-201 (gene therapy for MYBPC3-associated hypertrophic cardiomyopathy), TN-401 (gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy), & TN-301 (HDAC6 inhibitor for conditions such as heart failure with preserved ejection fraction & Duchenne muscular dystrophy).
  • The company utilizes integrated internal capabilities to develop novel medicines based on genetic insights for both rare genetic disorders & prevalent heart conditions.
  • Investor & media inquiries can be directed to Michelle Corral (IR@tenayathera.com) or Anne-Marie Fields of Precision AQ (annemarie.fields@precisionaq.com).